New therapy targeting LCN2 for KRAS lung cancer
Targeting LCN2, a novel therapy for lung cancer
A treatment that blocks a protein called LCN2 aims to help people with KRAS-mutant non-small cell lung cancer respond better to immunotherapy and other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11239821 on NIH RePORTER |
What this research studies
This project looks at whether blocking LCN2, a protein released by tumors, can help your immune system attack KRAS-driven non-small cell lung cancer. Researchers use genetic CRISPR screens and laboratory models, including studies in mice, to find how LCN2 suppresses anti-tumor T cells. They plan to develop ways (such as antibodies or inhibitors) to neutralize LCN2 and test whether adding those to current immunotherapies improves tumor control.
Who could benefit from this research
Good fit: People with KRAS-mutant non-small cell lung adenocarcinoma, especially those whose tumors resist standard treatments, would be the main candidates.
Not a fit: Patients without KRAS-driven lung cancer or whose tumors do not show high LCN2 levels are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could make immunotherapy and standard treatments work better for people with KRAS-driven lung cancer.
How similar studies have performed: LCN2 targeting is a newer, largely untested approach in patients, though other therapies that boost anti-tumor immunity have benefited some cancer patients.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Papagiannakopoulos, Thales — New York University School of Medicine
- Study coordinator: Papagiannakopoulos, Thales
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.